Browse News
Filter News
Found 156 articles
-
Annoviant™ Awarded $2.99 Million NIH Grant to Advance TxGuard™ Pulmonary-Valved Conduit for Pediatric Heart Disease
4/16/2024
Annoviant™, Inc. proudly announces receipt of a $2.99 million grant from the National Institutes of Health.
-
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
4/2/2024
Annovis Bio, Inc., a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.
-
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
4/1/2024
Annovis Bio, Inc. announced the publication of new data from an earlier study supporting buntanetap as a translational inhibitor of amyloid precursor protein in patients with early Alzheimer’s Disease.
-
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
3/20/2024
Annovis Bio, Inc. today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients with mild to moderate Alzheimer’s disease (AD).
-
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
2/14/2024
Annovis Bio, Inc. today announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer’s disease (AD).
-
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
1/30/2024
Annovis Bio, Inc., a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing of a patent application covering the use of buntanetap and its analogues for the treatment of neuropsychiatric indications.
-
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
1/24/2024
Annovis Bio, Inc. has announced a postponement in the Phase III study data release for buntanetap in Parkinson’s Disease.
-
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
12/5/2023
Annovis Bio, Inc. today announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with early Parkinson’s disease (PD).
-
Annovis Bio Appoints Andrew Walsh as Vice President Finance
12/1/2023
Annovis Bio, Inc., a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease announced the appointment of Andrew Walsh as VP, Finance.
-
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
11/27/2023
Annovis Bio, Inc. announced that AD phase II/III study of its lead compound buntanetap has exceeded full enrollment.
-
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
11/8/2023
Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) announced third quarter financial results for the period ended September 30, 2023, and reviewed recent accomplishments.
-
Annovis Bio Announces Pricing of $7.5 Million Public Offering
10/31/2023
Annovis Bio, Inc. announced the pricing of an underwritten public offering of 1,250,000 units consisting of one share of its common stock and an accompanying warrant.
-
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
10/30/2023
Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer’s Disease (AD) patients.
-
Annovis Bio Announces Launch of Proposed Public Offering - October 30, 2023
10/30/2023
Annovis Bio, Inc., a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease, announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock and an accompanying warrant to purchase shares of common stock.
-
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
10/24/2023
Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is presenting two posters at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 annual conference held in Boston, Massachusetts, from October 24-27.
-
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
10/12/2023
Annovis Bio, Inc. today announced that the independent statistical group concluded that its Phase 2/3 AD study was sufficiently powered to continue as originally planned without the addition of patients.
-
Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
8/15/2023
Annovis Bio, Inc. announced second quarter financial results for the period ended June 30, 2023, and reviewed recent accomplishments.
-
BioSpace rounded up companies with products for Alzheimer’s, ALS, Parkinson’s and Huntington’s in the final stages of clinical testing.
-
Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
7/18/2023
Annovis Bio, Inc. (NYSE: ANVS ), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), presented three posters at the Alzheimer’s Association International Conference (AAIC) 2023 annual meeting held in Amsterdam, Netherlands, from July 16-20.
-
Annovis Bio Announces the Filing of a Groundbreaking Patent
6/27/2023
Annovis Bio, Inc. announces the creation of a novel crystalline form of buntanetap (ANVS402), and the filing of a new composition of matter provisional patent with the U.S. Patent and Trademark Office.